Authors
Ning Yang, Jialu Zhuo, Zhihua Qu, Zixiang Li, Wei Li, Yiqiu Chen, Mingbo Gao, Ting Han
Published in
Clinical rheumatology. Oct 21, 2025. Epub Oct 21, 2025.
Abstract
The relationship between the calcium-phosphorus product (Ca × P) and hyperuricemia (HUA) has not been thoroughly explored. This study sought to investigate this association across BMI groups in US adults.
A cross-sectional analysis was conducted using the 2017-2018 National Health and Nutrition Examination Survey (NHANES) dataset (N = 5068). The association was evaluated through restricted cubic splines, logistic regression, and mediation analysis.
Participants in the highest quartile of Ca × P had a 1.31-fold higher odds of HUA (OR 1.31; 95% CI 1.04-1.65) compared to those in the lowest quartile. A positive linear association between Ca × P and HUA was observed among overweight or obese individuals (OR 1.04; 95% CI 1.01-1.08 and OR 1.04; 95% CI 1.01-1.06, respectively). In the obese subgroup, those in the highest Ca × P quartile had a 1.50-fold increased odds of HUA (OR 1.50; 95% CI 1.11-2.03). Moreover, serum triglycerides mediated 23.12% of the association between Ca × P and HUA in obese adults, showing differential effect patterns.
Ca × P levels were positively associated with a greater prevalence of HUA, especially in the overweight or obesity population. Serum triglycerides play a crucial mediating role in the relationship between Ca × P and HUA among obese people. Key Points • Elevated per Ca × P level is significantly associated with a 3% increased risk of hyperuricemia among US adults, with individuals in the highest quartile exhibiting 1.31-fold higher odds compared to those in the lowest quartile. • The association between Ca × P and hyperuricemia is notably stronger in overweight and obese populations, with obese adults in the highest Ca × P quartile showing a 1.5-fold increased risk of hyperuricemia. • Serum triglycerides mediate 23.12% of the relationship between Ca × P and hyperuricemia in obese individuals, indicating a substantial metabolic pathway influencing hyperuricemia development in this high-risk group.
PMID:
41118074
Bibliographic data and abstract were imported from PubMed on 21 Oct 2025.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 42
- Comments 0